Some randomized controlled trials showing a comparable mean A1C percentage during isophane (NPH)-based MDI and long-acting analog–based MDI in type 1 diabetes
| . | Mean A1C (%) . | . | |
|---|---|---|---|
| . | NPH . | Analog . | |
| Raskin et al. (21) | 7.6 | 7.5 (glargine) (NS) | |
| Ratner et al. (31) | 7.5 | 7.5 (glargine) (NS) | |
| Hermansen et al. (23) | 8.1 | 7.9 (detemir) (NS) | |
| Home et al. (24) | 7.9 | 7.8 (detemir) (NS) | |
| Russell-Jones et al. (22) | 8.4 | 8.3 (detemir) (NS) | |
| . | Mean A1C (%) . | . | |
|---|---|---|---|
| . | NPH . | Analog . | |
| Raskin et al. (21) | 7.6 | 7.5 (glargine) (NS) | |
| Ratner et al. (31) | 7.5 | 7.5 (glargine) (NS) | |
| Hermansen et al. (23) | 8.1 | 7.9 (detemir) (NS) | |
| Home et al. (24) | 7.9 | 7.8 (detemir) (NS) | |
| Russell-Jones et al. (22) | 8.4 | 8.3 (detemir) (NS) | |
NS, no significant difference between groups.